The Federal Trade Commission (FTC) has sent Zimmer Holdings, Inc. and Biomet, Inc. a “Second Request” for additional information in connection with their proposed merger.
FTC Sends “Second Request” to Zimmer/Biomet

According to former FTC attorney Darren Tucker, only about 4% of all deals receive a formal second request for information. Tucker worked on the Johnson & Johnson/Synthes merger while at the agency. This second request follows European regulators pausing their review of the deal until further information is provided by the companies.
Tucker, now at Bingham McCutchen, told OTW on July 2, 2014, that the issuance of a second request is not surprising, given the sizable overlaps between the two companies. “The parties still have good prospects for FTC approval of their transaction without conditions, on account of the three strong rivals that will remain in the hip and knee segments and the sophistication of the customers.”
Second Request
He said the second request gives the FTC an opportunity to obtain additional information from the parties, their customers, and other market participants.
“At the Second Request stage, the FTC can compel documents and information from third parties, rather than rely on voluntary submissions. Some of the things the FTC will be looking at include the extent to which the parties’ ordinary-course documents discuss competition between the firms, the frequency and intensity of competition between the two firms for sales, the similarity of the two firms’ products, the ability of rivals to reposition their product offerings in response to the merger, and potential efficiencies from the transaction, ” added Tucker.
Compliance with a second request, according to Tucker, typically takes about five months, followed by an additional one-month waiting period for the FTC to make an enforcement decision.
“Quick Look”
However, when the FTC’s concerns are less serious or are focused on a particular area, Tucker said it may do a so-called “quick look” investigation, which focuses on one or two dispositive issues while deferring compliance with the full second request. “It would not be surprising for the FTC to do a ‘quick look’ investigation here, focusing on the ability of customers to obtain competitive products from other suppliers in the event that the merged firm tried to raise prices post-transaction.”
Bank of America analyst Bob Hopkins estimates that a Zimmer/Biomet combined shoulder market share would be roughly 50% and in partial knees, the merged companies would be the #1 player. In Hopkins’ view, if Zimmer/Biomet need to divest one of their shoulder or partial knee businesses, “there would be ready buyers for either.”
A statement from Zimmer said the companies still expect to close the transaction in the first quarter of 2015.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.